Sandoz demonstrates innovation strength at “Long Night of Research“
April 11, 2014
On April 4, Sandoz participated for the first time in the “Long Night of Research” in Innsbruck, Austria.
The “Long Night of Research” is a nationwide event that takes place every two years and brings together science, research and industry to provide insight into innovation. Visitors young and old were able to experience the world of biotechnology close up.
The “The Long Night of Research“ was held for the sixth time at venues across Austria and this year attracted around 136,500 visitors. It is Austria’s biggest domestic public event in which Austrian top research and innovative technologies present their work in a transparent and accessible form.
Sandoz’s development and production experts set up five exciting research stations where they demonstrated how antibiotics are made, why some medications are injected, and how gene technology improves our lives. They also showed fungus under the microscope – it is a little-known fact that fungi are the “cell factories” for life-saving antibiotics. Visitors also learned how fermentation, purification and filling work.
The booths where people were able to personally get involved attracted big crowds – especially kids: For example, using spore suspension, visitors were able to sketch their own “fungus smileys” on petri dishes containing nutrients. Also, together with the Sandoz experts, they were able to discover what the genetic information of strawberries looks like and why a jelly fish gene causes bacteria to glow.
The Sandoz booth attracted approximately 2,000 visitors over the course of the evening. For Sandoz, the “Long Night of Research” was a resounding success – and an opportunity to demonstrate its research and innovation prowess.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.